Hikma gets rituximab in deal with Celltrion

Hikma Pharmaceuticals has reached its third biosimilar licensing agreement with Celltrion, acquiring exclusive rights to distribute and sell the South Korean firm’s Truxima (rituximab) biosimilar in the Middle East and North Africa (MENA).